YPSN.SW Stock Analysis
YP
Neutral
Based on Eyestock quantitative analysis, YPSN.SW`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Ypsomed Holding AG engages in the development and manufacture of injection systems for self-medication of drugs by patients, most notably used to treat diabetes. The company is headquartered in Burgdorf, Bern and currently employs 2,000 full-time employees. The company went IPO on 2004-09-22. The firm develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The firm operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The firm operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.